|Home | About | Journals | Submit | Contact Us | Français|
The aim was to identify clinical predictors for survival and examine treatment outcome in patients with high-grade glioma (HGG).
The authors retrospectively reviewed medical records of patients who was diagnosed HGG between January 2007 and December 2009. Demographic data, radiological data and treatment data of patients were reviewed and analyzed.
A total of 100 patients were analyzed. There was no difference in demographic data between Grade III and IV glioma. Patients with HGG had median survival time (MST) 18 months, The MST of patients with Grade III and IV glioma were 26 and 13 months, respectively. In this study, only anaplastic oligoastrocytoma and radiotherapy did impact strongly on survival of patients with HGG. In patients with Grade III and IV glioma, radiotherapy found to have influence on survival.
Patients with HGG in Prasat Neurological Institute had short survival resemble to other previous study. The clinical predictors for survival of patients were identified on multivariate analysis.
Glioma was classified into 4 grades according to WHO classification of tumor of the central nervous system (CNS) on the basis of their degree of malignancy. Grade III and IV glioma, anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), mixed anaplastic oligoastrocytoma (AOA) and glioblastoma (GBM), were known as high-grade glioma (HGG), which carried poor prognosis despite intensive treatments with surgery, radiotherapy, and chemotherapy.
Although the current standard treatment for HGG are maximal resection followed by radiotherapy with concomitant and adjuvant chemotherapy including temozolomide,[3,4,5] median survival time (MST) of GBM and AA were only <2 years and 2-5 years, respectively.[4,5,6,7]
There are several variables that could influence prognosis of patients with HGG such as age, performance status, tumor location, and extent of resection.[8,9,10,11,12,13,14] Therefore, assessment of patients by these variables may enable them receiving appropriate treatments and improve treatment outcome.
The purpose of this study was to identify clinical predictors of treatment outcome in HGG treated with combined modality approach in Prasat Neurological Institute and to examine the survival time of HGG patients at a single institute.
All patients who underwent surgery for diagnosed HGG (AA, AO, AOA and GBM) between January 2007 and December 2009 were included in this study. The authors reviewed medical records on patient characteristics and all of treatment modalities in each patient. The incomplete data on medical records were excluded.
Age, sex, Karnofsky performance status (KPS), payment and neurological status in each patients were reviewed. The KPS was dichotomized at <70 based on Radiation Therapy Oncology Group (RTOG) Recursive Partitioning Analysis (RPA).
Tumor imaging characteristics were reviewed. Tumor size had a cut-off value at 4 cm because the previous studies have shown that it was significant for survival at this value.[10,17] Tumor location with regard to proximity to eloquent brain was characterized by functional grade as described by Sawaya, et al. [Table 1]. Tumor necrosis [Figure 1], degree of mass effect, surrounding edema and enhancement of tumor mass were also measured and recorded using the methods of Hammoud, et al. [Table 2].
All treatment modalities included surgery, radiotherapy and chemotherapy were reviewed. Extent of tumor resection were classified into total resection, which defined as no residual gross tumor intraoperatively and on postoperative image, subtotal resection and biopsy. The radiotherapy and chemotherapy data derived from the medical records. Duration from surgery to radiotherapy was also calculated in all patients.
Parametric data were expressed as means ± standard deviations and compared via the Student's t-test. Nonparametric data were expressed as median values (interquartile range) and compared via the Mann-Whitney U-test. Percentages were compared via the Chi-square test or Fisher exact test based on sample size. Survival time was calculated from the date of first treatment until the date of death. The record was ended at January 2012. Survival curves were analyzed using Kaplan-Meier method and the log-rank test. The univariate and multivariate analysis of prognostic factors for survival were performed using Cox proportional hazards model. Hazard ratios and their 95% confidence intervals (CIs) were calculated. Statistical analyses were performed using the Statistical Package for the Social Sciences 19.0 (SPSS, Inc., Chicago, IL, USA). The author defined P value below 0.05 as significant.
There were 121 patients who were diagnosed HGG during that time. Twenty one patients were excluded from this study because of incomplete data. Table 3 shows a demographic data of all 100 patients. Median follow-up time was 14 months (1-44 months). The data of each subgroups those are WHO Grade III and Grade IV glioma are also shown. There were no significant difference in age, sex, KPS, weakness, aphasia and imaging characteristics between the 2 subgroups. Surgical treatment was mostly resection rather than biopsy, especially in patients with Grade IV glioma (P = 0.06). Hence, the duration of operation and estimated blood loss in patients with Grade IV glioma were much more than in patients with Grade III glioma (P = 0.01, 0.01). No difference between patients in both Grade III and Grade IV glioma received the adjuvant therapy (temozolomide, gliadel and other chemotherapy) (P = 0.47, 0.46, 0.33, respectively).
The MST for all patients from the time of surgery was 18 (95% CI 13.4-22.6) months. The MST of patients with Grade III and IV glioma was 26 (95% CI 19-33) and 13 (95% CI 10.2-15.8) months, respectively. Figure 2 shows the survival curve of patients with Grade III and IV glioma. The log-rank test showed that patient with Grade III glioma had significantly longer survival time than Grade IV glioma (P = 0.004). The authors also analyzed the survival curve of patients with each histological type [Figure 3]. The log-rank test also confirmed that histological type did impact on survival of these patients (P = 0.004). It is shown that there were little patients diagnosed AO and AOA and they had better survival time than AA (P = 0.042). When compared the survival time between patients with AA (MST = 21 months, 95% CI = 17.7-24.3) and GBM [Figure 4], the log-rank test showed that the difference was not significant between these two groups (P = 0.85).
The clinical predictors for survival of all patients were analyzed by Cox proportional hazards model. On univariate analysis, KPS, histological type (those were AO and AOA) and radiotherapy had effect on survival (P = 0.023, 0.019 0.014, and 0.000, respectively). On multivariate analysis, only AOA and radiotherapy did impact on survival of these patients (P = 0.035 and 0.000, respectively) [Table 4].
In patients with Grade IV glioma, there was only radiotherapy found to have influence on survival in both univariate and multivariate analysis (P = 0.000, <0.001). Finally, the Cox analysis was performed on patients with Grade III glioma. Patients with civil servants medical scheme and radiotherapy had influence on survival in univariate analysis (P = 0.005 and 0.000, respectively). However in multivariate analysis, only radiotherapy was the significant factor on survival (P < 0.001) [Table 5].
High-grade glioma composed of WHO Grade III and Grade IV glioma which is the most common primary brain tumors. They represent 80% of malignant CNS tumors. Although there are combination treatment between surgery, radiotherapy and chemotherapy, they carry poor prognosis and have short MST.
The previous studies have shown that MST of patients with Grade III and Grade IV glioma, on average, were 2-5 years and <2 years, respectively[4,7,25] In Thailand, Siangprasertkij and Navalitloha from Chulalongkorn University, reported the MST of Grade III and Grade IV glioma was 20 and 9 months, respectively. Chansriwong and Sirisinha from Ramathibodi Hospital, Mahidol University, reported the overall survival time in patients with HGG was 604.04 days. The treatment outcomes in this study are comparable to other previous studies [Table 6].
There are many studies about clinical predictors for survival in patients with HGG. Most studies have been reported that age, performance status and tumor grade were independent important prognostic factors.[11,28,29] The RTOG used RPA to analyze survival in 1,578 patients with HGG. There are six prognostic classes that primarily used the variable of age, histology, mental status, KPS, symptom duration and extent of resection. Laws et al. published data from the Glioma Outcome Project that resection instead of biopsy, age <60 and KPS >70 were all significantly correlated with outcome. McGirt et al. have recently reported extent of resection was associated with improved survival independent of age, KPS, tumor grade, or adjuvant treatment for HGG. The independent prognostic factors in this study are oligodendroglial component and radiotherapy.
The natural history of HGG is different according to tumor grade and histopathology. It has been universally accepted that the prognosis of Grade IV glioma is worse than Grade III glioma. Furthermore, this study shows mixed oligoastrocytoma subtype had a better prognosis which is compatible with the previous studies.[25,29,30,31]
Radiotherapy has been well-documented as one of the advance treatment modalities for HGG.[1,4,32,33,34] It is strongly correlated with survival in HGG. The multivariate Cox analysis in this study also reported it was a significant predictor for survival in patients with HGG. Patients in this study were received radiotherapy 62% (67.9% in Grade III, 54.5% in Grade IV). Median time from surgery to radiation was about 2 months. This seems to be less effective treatment and may have effect on survival. Because there is no radiotherapy in our institute. All patients need to be transferred for radiation in the other hospitals. Hence, there may be some patients loss between the transferring. Furthermore, some patients refused to be treated with radiation due to their personal opinions. This is an important problem for the current health care system and have to be improved immediately [Table 7].
It is important to note that there were some limitations to this study. This study is retrospective, thus potentially subject to sources of bias and variation. The number of patients is quite low. Data in this study were from medical records and population database of the ministry of public health. There was no detail in some aspects such as dose and technique of radiation, dose and duration of temozolomide and other chemotherapy. However, it is encouraging that the demographic characteristics of the patients and the overall survival data are very similar to those reported in other published studies.
This retrospective study at a single institute shows that patients with HGG had a short survival resemble to the other previous studies. The clinical predictors for survival of patients were identified on multivariate analysis. Patients should be encouraged to received suitable treatment by the new health care system.
There are no conflicts of interest.